Experimental Hematology
Volume 34, Issue 10 , Pages 1385-1392 , October 2006

JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model

  • Naofumi Uesato

      Affiliations

    • Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
    • Corresponding Author InformationOffprint requests to: Naofumi Uesato, Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
    • ,
  • Kenji Fukui

      Affiliations

    • Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
    • ,
  • Junji Maruhashi

      Affiliations

    • Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
    • ,
  • Arinobu Tojo

      Affiliations

    • Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    • ,
  • Nobuyuki Tajima

      Affiliations

    • Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan

Received 9 March 2006 ,Revised 16 May 2006 ,Accepted 25 May 2006.

References 

  1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051–1062
  2. Ohno R, Kobayashi T, Tanimoto M, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993;71:3888–3895
  3. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood. 1997;89:2311–2318
  4. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52:363–371
  5. Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875
  6. Bruserud Ø, Ryningen A, Wergeland L, Glenjen N, Gjertsen BT. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 2004;89:391–402
  7. Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud Ø. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res. 2005;29:185–196
  8. Glenjen N, Hatfield K, Bruserud Ø. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. Eur J Haematol. 2005;74:24–34
  9. Oster W, Cicco NA, Klein H, Hirano T, Kishimoto T, Lindemann A. Participation of cytokine interleukin 6, tumor necrosis factor-α, and interleukin 1-β secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest. 1989;84:451–457
  10. Rogers SY, Bradbury D, Kozlowski R, Russell NH. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol. 1994;22:593–598
  11. Foss B, Mentzoni L, Bruserud Ø. Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. J Hematother Stem Cell Res. 2001;10:81–93
  12. Glenjen N, Hovland R, Wergeland L, Wendelbo O, Ernst P, Bruserud Ø. The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. Eur J Haematol. 2003;71:163–173
  13. Vinante F, Rigo A, Vincenzi C, et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia. 1993;7:1552–1556
  14. Tobler A, Moser B, Dewald B, et al. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood. 1993;82:2517–2525
  15. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717–3721
  16. Aguayo A, Kantarjian H, Estey E, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95:1923–1930
  17. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–793
  18. de Bont ES, Vellenga E, Molema G, van Wering E, de Leij LF, Kamps WA. A possible role for spontaneous interleukin-8 production by acute myeloid leukemia cells in angiogenesis related process: work in progress. Med Pediatr Oncol. 2001;37:511–517
  19. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637–2644
  20. Komorowski J, Jerczyńska H, Siejka A, et-al. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. In press.
  21. Rosiñol L, Cibeira MT, Segarra M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine. 2004;26:145–148
  22. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881–894
  23. Greenberg P. Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. Ann Rheum Dis. 2001;60:iii41–iii42
  24. Steins MB, Padro T, Bieker R, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood. 2002;99:834–839
  25. Kakutani M, Takeuchi K, Waga I, Iwamura H, Wakitani K. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999;48:461–468
  26. Iwamura H, Sato M, Wakitani K. Comparative study of glucocorticoids, cyclosporine A, and JTE-607 [(-)-Ethyl-N[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]-L-phenylalaninate dihydrochloride] in a mouse septic shock model. J Pharmacol Exp Ther. 2004;311:1256–1263
  27. Sasaki J, Fujishima S, Iwamura H, Wakitani K, Aiso S, Aikawa N. Prior burn insult induces lethal acute lung injury in endotoxemic mice: effects of cytokine inhibition. Am J Physiol Lung Cell Mol Physiol. 2003;284:270–278
  28. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol. 2002;64:1079–1090
  29. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158–1165
  30. Sugiyama H, Inoue K, Yamagami T, Soma T, Miyake S, Hirata M. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma. 1996;21:49–52
  31. Russell NH. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev. 1992;6:149–156
  32. Oster W, Lindermann A, Horn S, Mertelsmann R, Herrmann F. TNF-α but not TNF-β induces secretion of colony-stimulation factor for macrophages (CSF-1) by human monocytes. Blood. 1987;70:1700–1703
  33. Munker R, Gasson J, Ogawa M, Koeffler HP. Reconbinant human TNF induces production of granulocyte-monocyte colony-stimulation factor. Nature. 1986;323:79–83
  34. de Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113:296–304
  35. Hsu HC, Lee YM, Tsai WH, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002;63:64–69
  36. Dumitru CD, Ceci JD, Tsatsanis C, et al. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103:1071–1083
  37. Kooijman R, Coppens A, Hooghe-Peters E. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal–regulated protein kinase. Cell Signal. 2003;15:1091–1098

PII: S0301-472X(06)00333-X

doi: 10.1016/j.exphem.2006.05.016

Experimental Hematology
Volume 34, Issue 10 , Pages 1385-1392 , October 2006

Article Tools

* Image Usage & Resolution